Extern

Extern Bio is a biotechnology company focused on developing first-in-class therapies for neurodegenerative diseases by targeting the extracellular proteostasis system. The company's approach involves utilizing recombinant versions of naturally occurring extracellular chaperones, such as Clusterin and Alpha-2-macroglobulin, to prevent and reverse the aggregation of pathogenic proteins like amyloid-beta and alpha-synuclein. By enhancing the body's innate ability to clear misfolded proteins outside of cells, Extern Bio aims to provide disease-modifying treatments for conditions including Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The company's research is based on pioneering work regarding the role of chaperones in maintaining protein homeostasis in the interstitial fluid of the brain. Currently in the pre-clinical stage, Extern Bio is advancing a pipeline of biologic candidates designed to restore proteomic balance and prevent neuronal death.